1-3 of 3
Olivier Barriere
Close
Sort by
Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses to Demonstrate the Link of Causality between ADAMTS13 and the Clinical Effects of Recombinant ADAMTS13 Compared to Plasma-Based Therapies

Munjal Patel, Olivier Barriere, Paul Diderichsen, Huijuan Xu, Andy Zhu, Jean François Marier, Björn Mellgård, Wenping Wang, Indranil Bhattacharya
Journal: Blood
Blood (2023) 142 (Supplement 1): 1260.
https://doi.org/10.1182/blood-2023-189314
Published: 2023
Journal Articles

Exposure-Response Relationship between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rVWF, vonicog alfa) in Patients with Severe Von Willebrand Disease (VWD)

Yi Wang, Gülden Özen, Björn Mellgård, Jean Francois Marier, Olivier Barriere, Grygoriy Vasilinin, Indranil Bhattacharya
Journal: Blood
Blood (2021) 138 (Supplement 1): 2104.
https://doi.org/10.1182/blood-2021-146153
Published: 2021
Journal Articles

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Phu V. Troung, MD F.A.C.P., Marc Saltzman, MD, Alberto Bessudo, MD, William Jawien, MD, Roger M. Lyons, MD F.A.C.P., Dmitriy Berenzon, MD, Raul Mena, MD, Nasiema Wingate-Pearse, Olivier Barriere, PhD, Hali E. Beeson, Paul F. Glidden, PhD, Gavin S. Choy, PharmD, MBA, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4074.
https://doi.org/10.1182/blood.V126.23.4074.4074
Published: 2015